American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 358-361 , March 2008

Cystatin C: Research Priorities Targeted to Clinical Decision Making

  • Michael G. Shlipak, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael G. Shlipak, MD, Departments of Medicine, Epidemiology and Biostatistics, Veterans Administration Medical Center, San Francisco, CA 94121.

References 

  1. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985;45:97–101
  2. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002;40:221–226
  3. Koenig W, Twardella D, Brenner H, et al. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321–327
  4. Jernberg T, Lindahl B, James S, et al. A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–2348
  5. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45:268–271
  6. Shlipak MG, Sarnak M, Katz R, et al. Cystatin-C and risk for mortality and cardiovascular disease in elderly adults. N Engl J Med. 2005;352:2049–2060
  7. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: The health, aging, and body composition study. J Am Soc Nephrol. 2006;17:254–261
  8. Stevens LA, Levey AS. Chronic kidney disease in the elderly—how to assess risk. N Engl J Med. 2005;352:2122–2124
  9. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406
  10. Köttgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51:385–394
  11. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–246
  12. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16:1404–1412
  13. Odden MC, Chertow GM, Fried LF, et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol. 2006;164:1180–1189
  14. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047

PII: S0272-6386(08)00039-5

doi: 10.1053/j.ajkd.2008.01.002

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 358-361 , March 2008

Article Tools